Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Narrative)

v3.22.1
Commitments and Contingencies (Details Narrative)
3 Months Ended 12 Months Ended
Mar. 04, 2022
USD ($)
Mar. 03, 2022
USD ($)
Dec. 29, 2021
USD ($)
Dec. 02, 2021
USD ($)
Nov. 19, 2021
ft²
Aug. 06, 2021
USD ($)
Mar. 26, 2021
USD ($)
Oct. 05, 2020
Mar. 31, 2021
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Loss Contingencies [Line Items]                      
Project fees                     $ 2,100,000
Initial payment     $ 191,527 $ 541,527              
Periodic payment to be made                     191,527
Final payment                     192,470
Other Commitments, Description               On October 5, 2020, GT Biopharma entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently signed five Statements of Work for the research and development of products for use in clinical trials. At December 31, 2021, the Company’s commitments in relation to these Statements of Work and any related Change Orders totaled approximately $13.0 million, of which $7.5 million was incurred at that date and an additional $5.5 million is in process during fiscal year 2022.      
Received upfront payment                     200,000
Annual maintanance fee                     $ 100,000
Royalty fee percentage                     0.04
Annual royalty payments                 $ 250,000    
Performance milestone payments                 3,100,000   $ 3,100,000
Sales milestone payments                 1.0   1,000,000.0
Gross sales                 250,000,000   250,000,000
Sales revenue                 5.0 $ 5.0  
Cummulative gross sales                 500,000,000 $ 500  
Upfront license fee             $ 20,000        
License maintenance fee, receivable                     5,000
[custom:MaintananceFee]                 $ 2.0    
Aimmune Therapeutics Inc [Member]                      
Loss Contingencies [Line Items]                      
Area of Land | ft²         4,500            
Lessee, Operating Sublease, Option to Extend         commencement date of January 1, 2022 and maturing on June 30, 2024            
Minimum [Member]                      
Loss Contingencies [Line Items]                      
Annual royalty payments                     250,000
[custom:NetSalesPercentage]                 0.025    
Maximum [Member]                      
Loss Contingencies [Line Items]                      
[custom:NetSalesPercentage]                 0.05    
Master Services Agreement [Member] | Cytovance Biologics, Inc. [Member]                      
Loss Contingencies [Line Items]                      
Commitment amount for services, total                     13,000,000.0
Commitment cost incurred                     7,500,000
Compensation cost expected to be incurred in future                     $ 5,500,000
Sheffield Properties [Member]                      
Loss Contingencies [Line Items]                      
Litigation Settlement, Expense           $ 100,000          
Subsequent Event [Member]                      
Loss Contingencies [Line Items]                      
Litigation Settlement, Expense $ 425,000,000,000 $ 400,000